Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00518479

Enrollment

Registered

2007-08-20

Start date

2003-09-30

Completion date

2004-04-30

Last updated

2012-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Left Ventricular Hypertrophy

Keywords

Hypertension, Left Ventricular Hypertrophy

Brief summary

Uncontrolled high blood pressure can cause heart muscle 'thickening', and this increases the likelihood of complications and death. The high blood pressure explains some but not all of this increase in heart size. This study will investigate the other causes, and will measure the heart muscle 'thickness' very accurately using the latest and most accurate technique called cardiac magnetic resonance imaging (MRI). The best way to treat this heart thickening remains to be determined. We hope to be able to show that by specifically targeting the cause of heart muscle thickening we can reduce its occurrence more effectively than by other standard means of blood pressure treatment

Interventions

DRUGBendroflumethiazide 2.5mg OD; Amlodipine 10mg OD

DRUGValsartan 160mg OD; Moxonidine 400mcg OD

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Recently diagnosed essential hypertension (within 6 months). * Age 25 to 80 years; Weight \< 100kg. * Sinus rhythm without significant ventricular or atrial ectopy.

Exclusion criteria

* Current angiotensin II receptor antagonist or ACE Inhibitor treatment. * Contra-indication to any of the protocol anti-hypertensive agents. * Angina requiring treatment with a Beta blocker or calcium antagonist * Any disease affecting the autonomic nervous system e.g. congestive cardiac failure, diabetes, neurological disease, malignancy, pregnancy. * Contraindication to MRI (pacemaker, intra-orbital debris, intra-auricular implants, intra-cranial clips, history of claustrophobia, inability to lie supine for 15 minutes etc).

Design outcomes

Primary

Measure	Time frame
The primary outcome measure is decrease in LV mass as assessed by cardiac MRI compared between the two treatment groups.	6 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026